The Role Of Neurosurgical Treatment In Prediction Of The Recurrenсе Of Cushing Disease
https://doi.org/10.17238/2072-3180-2021-4-80-89
Abstract
Cushing's disease (CD) is a rare disease with a clinical picture of hypercortisolism, caused by the presence of pituitary tumor and characterized by hypersecretion of adrenocorticotropic hormone (ACTH) and an increase in cortisol production by the adrenal gland. Surgical treatment is the first line of therapy. Preoperative identification is required to achieve complete tumor resection and to achieve clinical remission. The volume and type of surgical intervention depends on the characteristics of the tumor.
The results of the operation are assessed by radicality, postoperative complications and biochemical parameters. But one third of patients does not achieve remission after surgery. The reason for the lack of effect after surgery may be anatomical and morphological features of the tumor, and the experience of the surgeon and the surgical technique used. Knowledge of the features of surgical tactics and the intraoperative picture makes it possible to assess the prognosis of the risk of recurrence. Assessment of radicality can be carried out both immediately after the operation and in the delayed period.
Calculation of the risk of recurrence of the СD at the preoperative and postoperative periods allows you to optimize and personalize the algorithm for monitoring and early diagnosis of CD recurrence and for the next stage of treatment.
About the Authors
A. V. Andreeva
City Clinical Hospital name of V.V. Veresaev, Department of Healthcare of Moscow;
Endocrinological dispensary, Department of Healthcare of Moscow
Russian Federation
Russian Federation
endocrinologist, deputy chief
Russian Federation, 127644, Moscow, Lobnenskaya str., 10
M. B. Antsiferov
Endocrinological dispensary, Department of Healthcare of Moscow
Russian Federation
Russian Federation
professor, Ph.D., Chief Endocrinologist Moscow Healthcare Department
Russian Federation, 119034, Moscow, Prechistenka str., 37
References
1. Itsenko N.M. Tumor hypophisis with polyglandular symptoms, in connection with the review of the issue of central innervation of autonomic functions. Yugo-Vostochny Health Bulletin, 1924, № 3–4, p. 136. (In Russ.)
2. Nieman L.K. Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol., 2015 Oct; № 173(4), рр. 33–38. https://doi.org/10.1530/EJE-15-0464
3. Kalinin P.L., Kadashev B.A., Fomichev D.V., Kutin M.A., Astaf’eva L.I., Sharipov O.I., Shkarubo A.N., Tropinskaya O.F., Voronina I.A., Fomochkina L.A. Khirurgicheskoe lechenie adenom gipofiza [Surgical treatment for pituitary adenomas]. Zh Vopr Neirokhir Im N N Burdenko, 2017, pp. 95–107. (In Russ.)
4. Kalinin P.L. Surgical treatment of pituitary adenomas using endoscopic endonasal trans-sphenoidal approach. Moscow, 2009, 157 p. (In Russ.)
5. Aranda G., Ensenat J., Mora M. Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up. Pituitary, 2015, Vol. 18, № 1, pp. 142–149.
6. Grigoriev A.U. Neurosurgical treatment of patients with Cushing’s disease and acromegaly. Dr. med. Sci. diss. Moscow, 2011, 257 p. (In Russ.)
7. Mehta G.U. The history of pituitary surgery for Cushing disease. J Neurosurg., 2012, Vol. 116, № 2, pp. 261–268.
8. Kalinin P.L., Fomichev D.V., Kutin M.A., Kadashev B.A., Astaf’eva L.I., Shkarubo A.N., Alekseev S.N., Fomochkina L.A. Endoscopic endonasal surgery of pituitary adenomas (experience of 1700 operations). Zh Vopr Neirokhir Im N. N. Burdenko, 2012, № 3, pp. 26–33. (In Russ.)
9. Komotar R.J., Starke R.M., Raper D.M. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. Pituitary, 2012, Vol. 15, № 2, pp. 150–159.
10. Abdali A., Astaf Eva L., Trunin Y., Kalinin P., Golanov A., Abdali B., Chmutin G., Shkarubo A., Chaurasia B. Modern Methods of Stereotactic Radiosurgery and Radiotherapy for the Treatment of Cushing Disease. Neurol India, 2020, № 2, pp. 129–133.
11. Schito L. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. Trends in Cancer, 2016, Vol. 2, № 12, pp. 758–770.
12. Belaya Z.E. Early diagnosis of endogenous hypercortisolism. Canonical wnt signaling pathway and changes in bone metabolism in glucocorticoid osteoporosis. Dr. med. Sci. diss. Moscow, 2013, 293 p. (In Russ.)
13. Carr S.B., Kleinschmidt-DeMasters B.K., Kerr J.M. Negative surgical exploration in patients with Cushing’s disease: benefit of two-thirds gland resection on remission rate and a review of the literature. J Neurosurg., 2018, Vol. 129, № 5, pp. 1260–1267.
14. Nagata Y. Removal of the Medial Wall of the Cavernous Sinus for 128 Functional Pituitary Adenomas: A Technical Report and Pathologic Significance. World Neurosurg., 2019, Vol. 126, pp. 53–58.
15. Hou L. Suprasellar adrenocorticotropic hormone-secreting ectopic pituitary adenoma: case report and literature Review. Neurosurgery, 2002, Vol. 50, № 3, pp. 618–625.
16. Cappabianca P., Cavallo L.M., Colao A., de Divitiis E. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg., 2002, Aug; № 97(2), pp. 293–298.
17. Magro E., Graillon T., Lassave J. Complications Related to the Endoscopic Endonasal Transsphenoidal Approach for Nonfunctioning Pituitary Macroadenomas in 300 Consecutive Patients. World Neurosurg., 2016, Vol. 89, pp. 442–453.
18. Astaf’eva L.I., Kutin М.А., Mazerkina N.A. The rate of hyponatremia in neurosurgical patients (comparison between the data from the Burdenko Neurosurgical Instutite and the literature) and recommendations for the diagnosis and treatment. Zh Vopr Neirokhir Im N N Burdenko, 2016, Vol. 80, № 1, pp. 57–70. (In Russ.)
19. Clayton R.N. Mortality in Cushing’s Disease. Neuroendocrinology, 2010, Vol. 92, № 1, рр. 83–90
20. Esposito F., Dusick J.R., Cohan P., Moftakhar P., McArthur D., Wang C., Swerdloff R.S., Kelly D.F. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metabolism, 2006, Jan; № 91(1), pp. 7–13.
21. Petersenn S., Beckers A., Ferone D., van der Lely A. Bollerslev J., Boscaro M., Brue T., Bruzzi P., Casanueva F.F., Chanson P., Colao A, Reincke M, Stalla G, Tsagarakis S. Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol., 2015, № 6, pp. 227–239.
22. Braun L.T., Rubinstein G., Zopp S., Vogel F., Schmid-Tannwald C., Escudero M.P., Honegger J., Ladurner R., Reincke M. Recurrence after pituitary surgery in adult Cushing’s disease: a systematic review on diagnosis and treatment. Endocrine, 2020, № 70, pp. 218–231.
23. Ayala A., Manzano A.J. Detection of recurrent Cushing’s disease: proposal for standardized patient monitoring following transsphenoidal surgery. J Neuro-oncol., 2014, Sep; № 119(2), pp. 235–242.
24. Castinetti F., Martinie M., Morange I., Dufour H., Sturm N., Passagia J.G., Conte-Devolx B., Chabre O., Brue T. A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing’s disease. J. Clin. Endocrinol. Metab., 2009, Jun; № 94(6), pp. 1897–1903.
25. Ambrogio A.G., Andrioli M., De Martin M., Cavagnini F., Pecori Giraldi F. Usefulness of desmopressin testing to predict relapse during longterm follow-up in patients in remission from Cushing’s disease. Endocr. Connect., 2017, Nov; № 6(8), pp. 791–799.
26. Ikeda H., Abe T., Watanabe K. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J. Neurosurg., 2010, № 112(4), pp. 750–755.
Review
For citations:
Andreeva A.V., Antsiferov M.B. The Role Of Neurosurgical Treatment In Prediction Of The Recurrenсе Of Cushing Disease. Moscow Surgical Journal. 2021;(4):80-89. (In Russ.) https://doi.org/10.17238/2072-3180-2021-4-80-89
Views:
292
Email this article 